Table 2.

Serum Measures of Vitamin D Status and Bone Metabolism in Patients With Chronic Kidney Disease Treated With Placebo or Cholecalciferol (Vitamin D₃)^a,^b

	Placebo			Cholecalciferol
Analyte	Week 0	Week 6	Week 12	Week 0	Week 6	Week 12
Total	9.0		9.5	9.1		9.7
calcium,	(8.8–9.3)	…	(9.3–9.6)	(8.9–9.4)	…	(9.5–9.8)
mg/dL	n = 9		n = 10	n = 9		n = 10
25(OH)D,	18.6	21	19.5	17.3	44.5	49.4
ng/mL	(12.8–27.1)	(15.7–28.2)	(13.4–28.4)	(11.8–25.2)	(33.1–59.8)	(33.9–72.0)
	n = 10	n = 9	n = 10	n = 10	n = 7	n = 10
PTH, pg/mL	290.5	335.1	269.7	288.9	254.7	200.5
	(179.7–469.8)	(214.2–524.1)	(153.3–474.5)	(178.7–467.2)	(161.4–401.9)	(114.0–352.8)
	n = 10	n = 9	n = 10	n = 10	n = 7	n = 10
1,25(OH)2D,	29.7		30.8	29.1		40.2
pg/mL	(17.3–51.0)	…	(24.8–38.1)	(16.9–50.0)	…	(32.8–49.2)
	n = 9		n = 9	n = 10		n = 10
BAP, IU/L	18.4		22.0	20.3		20.4
	(10.2–33.3)	…	(19.3–25.0)	(13.4–30.5)	…	(18.0–23.1)
	n = 8		n = 8	n = 9		n = 9
CTX, pg/mL	0.36		0.24	0.34		0.29
	(0.18–0.74)	…	(0.14–0.40)	(0.15–0.76)	…	(0.18–0.49)
	n = 8		n = 8	n = 9		n = 9
TRAP5b,	2.9		3.5	3.8		3.2
pg/mL	(1.8–4.8)	…	(2.9–4.1)	(2.5–5.6)	…	(2.7–3.8)
	n = 9		n = 9	n = 10		n = 10

Abbreviations: BAP, bone-specific alkaline phosphatase; CTX, serum C-telopeptide; 1,25(OH)₂D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; TRAP5b, tartarate-resistant acid phosphatase isoform 5b.

^aBecause the data were log-transformed, the mean was exponentiated to express the results in the original unit of measurement; the result is the geometric mean. To compare the geometric means of the treatment and placebo groups, the geometric mean ratio is used. A ratio equal to 1 suggests no treatment effect.

^bData are presented as sample geometric mean (95% confidence interval for the true geometric mean).